What is the recommended treatment for spontaneous bacterial peritonitis (SBP)?

Treatment of Spontaneous Bacterial Peritonitis

For community-acquired SBP, immediately initiate IV third-generation cephalosporin (cefotaxime 2g IV every 6-12 hours) PLUS IV albumin (1.5 g/kg on day 1 and 1 g/kg on day 3) for 5-7 days. 1

Initial Empirical Antibiotic Selection

The choice of empirical antibiotics depends critically on the setting of infection acquisition:

Community-Acquired SBP

• First-line: IV third-generation cephalosporin (cefotaxime 2g every 6-12 hours or ceftazidime) 1
• Alternative options:
  • Amoxicillin-clavulanic acid (IV then oral switch) 2
  • Oral ofloxacin 400mg twice daily for uncomplicated cases (no renal failure, encephalopathy, GI bleeding, ileus, or shock) 2
  • Ciprofloxacin (IV to oral switch therapy) 2

Healthcare-Associated or Nosocomial SBP

Critical distinction: For patients with healthcare-associated infection, recent broad-spectrum antibiotic exposure, or presenting with sepsis/septic shock, you must use broader-spectrum coverage from the start. 1

• Recommended: Meropenem 1g every 8 hours PLUS daptomycin 6 mg/kg/day 3
  • This combination achieved 86.7% treatment success versus only 25% with ceftazidime in nosocomial SBP 3
  • The shift reflects increasing prevalence of gram-positive cocci and multidrug-resistant organisms in healthcare settings 4, 5

Do NOT use quinolones if the patient is already on quinolone prophylaxis, in areas with high quinolone resistance, or for nosocomial SBP 2

Mandatory Albumin Administration

IV albumin is non-negotiable and improves survival by preventing acute kidney injury (AKI) and hepatorenal syndrome, which are the main predictors of in-hospital mortality. 1

Albumin Dosing Protocol

• Day 1: 1.5 g/kg body weight within 6 hours of diagnosis
• Day 3: 1.0 g/kg body weight
• This regimen reduced mortality from 29% to 10% and decreased type 1 hepatorenal syndrome from 30% to 10% 2

Who Benefits Most from Albumin

Patients with baseline renal dysfunction (creatinine >1.0 mg/dL or BUN >30 mg/dL) or severe hepatic decompensation (bilirubin >4-5 mg/dL) derive the greatest benefit. 1, 2 However, given the mortality benefit and the real-world data showing albumin within 24 hours associated with 72% higher hazard of hospital discharge, 6 administer albumin to all SBP patients unless contraindicated.

Treatment Duration and Monitoring

Standard Duration

• 5-7 days of antibiotic therapy 1
• Some data support stopping antibiotics once PMN count drops below 250/mm³, which may shorten treatment duration 1

Mandatory 48-Hour Reassessment

Perform repeat paracentesis 48 hours after starting antibiotics to assess treatment response. 1

Treatment failure is defined as: PMN count decrease <25% from baseline 1

If treatment fails:

1. Broaden antibiotic spectrum immediately
2. Obtain abdominal imaging (CT scan) to rule out secondary bacterial peritonitis 1, 2
3. Adjust antibiotics based on culture sensitivities if available

You may skip repeat paracentesis only if an organism was isolated, it's susceptible to your antibiotic, and the patient is clinically improving. 1

Critical Management Considerations

Concurrent Medication Adjustments

• Hold non-selective beta-blockers if mean arterial pressure <65 mmHg or if AKI develops 1
• Avoid nephrotoxic antibiotics (aminoglycosides) 2

Multidrug-Resistant Organisms

MDRO infections are associated with:

• 2.24-fold increased in-hospital mortality 6
• Prolonged hospital length of stay 6
• This underscores the importance of choosing appropriate empirical coverage based on acquisition setting

Secondary Prophylaxis After Recovery

After successful treatment, patients have a 68% one-year recurrence risk without prophylaxis versus 20% with prophylaxis. 1

Recommended prophylaxis:

• Oral ciprofloxacin 500mg daily (norfloxacin no longer available in US) 1
• Alternative: rifaximin (showed 4% vs 14% 6-month recurrence compared to norfloxacin) 1

Common Pitfalls to Avoid

1. Delaying albumin administration - Give within 6 hours of diagnosis, not "when convenient"
2. Using third-generation cephalosporins for nosocomial SBP - These have high failure rates; use broader coverage 3
3. Failing to repeat paracentesis at 48 hours - This is how you catch treatment failures early 1
4. Continuing beta-blockers in hypotensive or AKI patients - These worsen outcomes 1
5. Using quinolones in patients already on quinolone prophylaxis - Resistance is virtually guaranteed 2

The 2021 AASLD guidelines 1 represent the most current, authoritative recommendations and should guide all management decisions, with recognition that nosocomial infections require deviation from traditional third-generation cephalosporin monotherapy based on compelling evidence of treatment failure. 3